ArticleBMC gastroenterology2025
Gastrointestinal symptoms in adults with Fabry disease and their associations with physical and mental health.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bridging Biochemical and Clinical Disease Burden in Fabry Disease: A Comparative Analysis of Lyso-Gb3, MSSI, DS3, and FASTEX.International journal of molecular sciences · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFabry disease is a rare X-linked lysosomal storage disorder that affects multiple organ systems, including the gastrointestinal tract. The aims were to characterize the prevalence, characteristics, and severity of gastrointestinal symptoms in patients with Fabry disease compared to the general population, and to investigate the relationships between these gastrointestinal symptoms with clinical outcomes, including disease severity (DS3), health-related quality of life, psychological distress, and pain.
methodsA cross-sectional study design was used. Adults (≥ 18 years) with Fabry disease attending regular follow-up appointments at Oslo University Hospital, Norway, were recruited. Participants completed validated measures in Norwegian language of gastrointestinal symptoms [Rome III and the Irritable Bowel Syndrome Severity Scoring System (IBS-SSS)], Short-Form Health Survey-36 (SF-36v2), Hospital Anxiety and Depression scale, and Brief Pain Inventory.
resultsThirty-five adults with Fabry disease participated (mean age = 48 years; 54% women). More than 70% of participants reported at least one gastrointestinal symptom. The frequencies of IBS-like symptoms (42%), bloating (68%), severe bloating (44%), and nausea (23%) were significantly higher in the Fabry disease group compared to the general population. The IBS-SSS total score showed that 40% had moderate to severe IBS symptoms. Bivariate correlations revealed that gastrointestinal symptoms (IBS-SSS) were significantly related to severity of Fabry disease (r = 0.47), the SF-36v2 physical component summary score (r = -0.39), and pain measures (r = 0.38-0.46).
conclusionsThe high frequency of gastrointestinal symptoms in adults with Fabry disease suggests routine gastrointestinal screening alongside pain monitoring in clinical practice. These symptoms were related to disease severity, physical quality of life, and pain. Abdominal pain was most common, while IBS-like symptoms, bloating and nausea also occurred more often than in the general population. Further research on symptom progression and diet is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.